|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Ruiz-Cordero R and Devine WP: Targeted
therapy and checkpoint immunotherapy in lung cancer. Surg Pathol
Clin. 13:17–33. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Travis WD, Brambilla E, Nicholson AG,
Yatabe Y, Austin JHM, Beasley MB, Chirieac LR, Dacic S, Duhig E,
Flieder DB, et al: The 2015 World Health Organization
Classification of Lung Tumors: Impact of Genetic, Clinical and
Radiologic Advances Since the 2004 Classification. J Thorac Oncol.
10:1243–1260. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schwartz AG and Cote ML: Epidemiology of
lung cancer. Adv Exp Med Biol. 893:21–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Popper HH: Progression and metastasis of
lung cancer. Cancer Metastasis Rev. 35:75–91. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vinod SK and Hau E: Radiotherapy treatment
for lung cancer: Current status and future directions. Respirology.
25 (Suppl 2):S61–S71. 2020. View Article : Google Scholar
|
|
7
|
Delaney GP and Barton MB: Evidence-based
estimates of the demand for radiotherapy. Clin Oncol (R Coll
Radiol). 27:70–76. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Giuranno L, Ient J, De Ruysscher D and
Vooijs MA: Radiation-induced lung injury (RILI). Front Oncol.
9:8772019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chandra RA, Keane FK, Voncken FEM and
Thomas CR: Contemporary radiotherapy: Present and future. The
Lancet. 398:171–184. 2021. View Article : Google Scholar
|
|
10
|
Wang Y, Gudikote J, Giri U, Yan J, Deng W,
Ye R, Jiang W, Li N, Hobbs BP, Wang J, et al: RAD50 Expression is
associated with poor clinical outcomes after radiotherapy for
resected non-small cell lung cancer. Clin Cancer Res. 24:341–350.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ashrafi A, Akter Z, Modareszadeh P,
Modareszadeh P, Berisha E, Alemi PS, Chacon Castro MDC, Deese AR
and Zhang L: Current landscape of therapeutic resistance in lung
cancer and promising strategies to overcome resistance. Cancers
(Basel). 14:45622022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Salama JK and Vokes EE: New radiotherapy
and chemoradiotherapy approaches for non-small-cell lung cancer. J
Clin Oncol. 31:1029–1038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee SY, Jeong EK, Ju MK, Jeon HM, Kim MY,
Kim CH, Park HG, Han SI and Kang HS: Induction of metastasis,
cancer stem cell phenotype, and oncogenic metabolism in cancer
cells by ionizing radiation. Mol Cancer. 16:102017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Busato F, Khouzai BE and Mognato M:
Biological mechanisms to reduce radioresistance and increase the
efficacy of radiotherapy: State of the art. Int J Mol Sci.
23:102112022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bivona TG and Doebele RC: A framework for
understanding and targeting residual disease in oncogene-driven
solid cancers. Nat Med. 22:472–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kirsch DG, Diehn M, Kesarwala AH, Maity A,
Morgan MA, Schwarz JK, Bristow R, Demaria S, Eke I, Griffin RJ, et
al: The future of radiobiology. J Natl Cancer Inst. 110:329–340.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sørensen BS, Andreassen CN and Alsner J:
Molecular Biomarkers in Radiation Oncology. Radiation Oncology.
Wenz F: Springer International Publishing, Cham; pp. 1–20. 2019,
View Article : Google Scholar
|
|
18
|
Baumann M, Krause M, Overgaard J, Debus J,
Bentzen SM, Daartz J, Richter C, Zips D and Bortfeld T: Radiation
oncology in the era of precision medicine. Nat Rev Cancer.
16:234–249. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Landeck L, Kneip C, Reischl J and
Asadullah K: Biomarkers and personalized medicine: Current status
and further perspectives with special focus on dermatology. Exp
Dermatol. 25:333–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zheng Q, Ding H, Wang L, Yan Y, Wan Y, Yi
Y, Tao L and Zhu C: Circulating Exosomal miR-96 as a novel
biomarker for radioresistant Non-Small-Cell lung cancer. J Oncol.
2021:58939812021. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Scott JG, Berglund A, Schell MJ, Mihaylov
I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, et al: A
genome-based model for adjusting radiotherapy dose (GARD): A
retrospective, cohort-based study. Lancet Oncol. 18:202–211. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
The Promise of Precision Medicine.
National Institutes of Health (NIH); 2020
|
|
23
|
Peinado-Serrano J and Carnero A: Molecular
radiobiology in Non-small cell lung cancer: Prognostic and
predictive response factors. Cancers (Basel). 14:22022022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang WC, Hsu FM and Yang PC: Precision
radiotherapy for non-small cell lung cancer. J Biomed Sci.
27:822020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nickoloff JA, Sharma N and Taylor L:
Clustered DNA Double-strand breaks: Biological effects and
relevance to cancer radiotherapy. Genes (Basel). 11:992020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gopal P, Yard BD, Petty A, Lal JC, Bera
TK, Hoang TQ, Buhimschi AD and Abazeed ME: The mutational landscape
of cancer's Vulnerability to ionizing radiation. Clin Cancer Res.
28:5343–5358. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhu DQ, Liu Y, Yu ZJ, Zhang RH, Li AW,
Gong FY, Wang W, Xiao W and Fan Q: The diverse analysis identifies
mutated KRAS associated with radioresistance in Non-Small cell lung
cancer. World J Oncol. 13:84–95. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang M, Kern AM, Hülskötter M, Greninger
P, Singh A, Pan Y, Chowdhury D, Krause M, Baumann M, Benes CH, et
al: EGFR-mediated chromatin condensation protects KRAS-mutant
cancer cells against ionizing radiation. Cancer Res. 74:2825–2834.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang M, Han J, Marcar L, Black J, Liu Q,
Li X, Nagulapalli K, Sequist LV, Mak RH, Benes CH, et al: Radiation
resistance in KRAS-mutated lung cancer is enabled by Stem-like
properties mediated by an Osteopontin-EGFR pathway. Cancer Res.
77:2018–2028. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gurtner K, Kryzmien Z, Koi L, Wang M,
Benes CH, Hering S, Willers H, Baumann M and Krause M:
Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by
radiation dose escalation or EGFR tyrosine kinase inhibition in
vivo. Int J Cancer. 147:472–477. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tanaka K, Hida T, Oya Y, Oguri T, Yoshida
T, Shimizu J, Horio Y, Hata A, Kaji R, Fujita S, et al: EGFR
mutation impact on definitive concurrent chemoradiation therapy for
inoperable stage III adenocarcinoma. J Thorac Oncol. 10:1720–1725.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lim YJ, Chang JH, Kim HJ, Keam B, Kim TM,
Kim DW, Paeng JC, Kang KW, Chung JK, Jeon YK, et al: Superior
treatment response and In-field tumor control in epidermal growth
factor Receptor-mutant genotype of stage III nonsquamous Non-small
cell lung cancer undergoing definitive concurrent
chemoradiotherapy. Clin Lung Cancer. 18:e169–e178. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sampath S, Rashdan S, Iyengar P, Mickel
TA, Zhang S, Ahn C, Gao A, Dowell JE, Zhang Y, Westover KD, et al:
Osimertinib plus consolidative radiotherapy for advanced EGFR
mutant non-small cell lung cancer: A multicentre, single-arm, phase
2 trial. EClinicalMedicine. 87:1034352025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Binkley MS, Jeon YJ, Nesselbush M, Moding
EJ, Nabet BY, Almanza D, Kunder C, Stehr H, Yoo CH, Rhee S, et al:
KEAP1/NFE2L2 mutations predict lung cancer radiation resistance
that can be targeted by glutaminase inhibition. Cancer Discov.
10:1826–1841. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhang X, Huang X, Cao Y, Mao Y, Zhu Y,
Zhang Q, Zhang T, Chang L and Wang C: Dynamic analysis of
predictive biomarkers for radiation therapy efficacy in non-small
cell lung cancer patients by next-generation sequencing based on
blood specimens. Pathol Res Pract. 253:1549722024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Su D, Ma S, Liu P, Jiang Z, Lv W, Zhang Y,
Deng Q, Smith S and Yu H: Genetic polymorphisms and treatment
response in advanced non-small cell lung cancer. Lung Cancer.
56:281–288. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bergamaschi D, Samuels Y, O'Neil NJ,
Trigiante G, Crook T, Hsieh JK, O'Connor DJ, Zhong S, Campargue I,
Tomlinson ML, et al: iASPP oncoprotein is a key inhibitor of p53
conserved from worm to human. Nat Genet. 33:162–167. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jin JY, Wang W, Ten Haken RK, Chen J, Bi
N, Sadek R, Zhang H, Lawrence TS and Kong FM: Use a survival model
to correlate single-nucleotide polymorphisms of DNA repair genes
with radiation Dose-response in patients with non-small cell lung
cancer. Radiother Oncol. 117:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yin M, Yan J, Martinez-Balibrea E,
Graziano F, Lenz HJ, Kim HJ, Robert J, Im SA, Wang WS,
Etienne-Grimaldi MC and Wei Q: ERCC1 and ERCC2 Polymorphisms
predict clinical outcomes of Oxaliplatin-based chemotherapies in
gastric and colorectal cancer: A systemic review and Meta-analysis.
Clin Cancer Res. 17:1632–1640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yang Z and Liu Z: Potential functional
variants in DNA repair genes are associated with efficacy and
toxicity of radiotherapy in patients with Non-Small-cell lung
cancer. J Oncol. 2020:31327862020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kelsey CR, Jackson L, Langdon S, Owzar K,
Hubbs J, Vujaskovic Z, Das S and Marks LB: A polymorphism within
the promoter of the TGFβ1 gene is associated with radiation
sensitivity using an objective radiologic endpoint. Int J Radiat
Oncol Biol Phys. 82:e247–e255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Xu T, Wei Q, Lopez Guerra JL, Wang LE, Liu
Z, Gomez D, O'Reilly M, Lin SH, Zhuang Y, Levy LB, et al: HSPB1
gene polymorphisms predict risk of mortality for US patients after
radio(chemo)therapy for non-small cell lung cancer. Int J Radiat
Oncol Biol Phys. 84:e229–e235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guo H, Bai Y, Xu P, Hu Z, Liu L, Wang F,
Jin G, Wang F, Deng Q, Tu Y, et al: Functional promoter-1271G>C
variant of HSPB1 predicts lung cancer risk and survival. J Clin
Oncol. 28:1928–1935. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Butkiewicz D, Krześniak M, Gdowicz-Kłosok
A, Giglok M, Marszałek-Zeńczak M and Suwiński R: Polymorphisms in
EGFR gene predict clinical outcome in unresectable Non-Small cell
lung cancer treated with radiotherapy and Platinum-Based
chemoradiotherapy. Int J Mol Sci. 22:56052021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Milas L, Fan Z, Andratschke NH and Ang KK:
Epidermal growth factor receptor and tumor response to radiation:
In vivo preclinical studies. Int J Radiat Oncol Biol Phys.
58:966–971. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wen J, Liu H, Wang L, Wang X, Gu N, Liu Z,
Xu T, Gomez DR, Komaki R, Liao Z and Wei Q: Potentially Functional
variants of ATG16L2 predict radiation pneumonitis and outcomes in
patients with non-small cell lung cancer after definitive
radiotherapy. J Thorac Oncol. 13:660–675. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Torres-Roca JF, Eschrich S, Zhao H, Bloom
G, Sung J, McCarthy S, Cantor AB, Scuto A, Li C, Zhang S, et al:
Prediction of radiation sensitivity using a gene expression
classifier. Cancer Res. 65:7169–7176. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Peinado-Serrano J, Quintanal-Villalonga Á,
Muñoz-Galvan S, Verdugo-Sivianes EM, Mateos JC, Ortiz-Gordillo MJ
and Carnero A: A Six-gene prognostic and predictive
Radiotherapy-based signature for early and locally advanced stages
in Non-Small-Cell lung cancer. Cancers (Basel). 14:20542022.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen Y, Zhou C, Zhang X, Chen M, Wang M,
Zhang L and Chen Y, Huang L, Sun J, Wang D and Chen Y: Construction
of a novel radioresistance-related signature for prediction of
prognosis, immune microenvironment and anti-tumour drug sensitivity
in non-small cell lung cancer. Ann Med. 57:24479302025. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Pustovalova M, Malakhov P, Guryanova A,
Sorokin M, Suntsova M, Buzdin A, Osipov AN and Leonov S:
Transcriptome-based traits of radioresistant sublines of non-small
cell lung cancer cells. Int J Mol Sci. 24:30422023. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ma Q, Geng K, Xiao P and Zeng L:
Identification and prognostic value exploration of radiotherapy
Sensitivity-associated genes in Non-Small-Cell lung cancer. Biomed
Res Int. 2021:59638682021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhao Y, Song Y, Zhao R, Zhao M and Huang
Q: Gene panel of persister cells as a prognostic indicator for
tumor repopulation after radiation. Front Oncol. 10:6077272020.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Gao J, Lu F, Yan J, Wang R, Xia Y, Wang L,
Li L, Chang L and Li W: The role of radiotherapy-related autophagy
genes in the prognosis and immune infiltration in lung
adenocarcinoma. Front Immunol. 13:9926262022. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Guo W-F, Lin R-X, Huang J, Zhou Z, Yang J,
Guo GZ and Wang SQ: Identification of differentially expressed
genes contributing to radioresistance in lung cancer cells using
microarray analysis. Radiat Res. 164:27–35. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Li Q, Shen L, Yang Y, Tai G, Zhu Q, Liu C,
Ge Q and Yi Q: Investigating the role of Lactate-related genes in
radiotherapy resistance of lung cancer by integrated bioinformatics
and experiment validation. J Cancer. 16:3296–3313. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Xu Q, Yu Z, Mei Q, Shi K, Shen J, Gao G,
Liu S and Li M: Keratin 6A (KRT6A) promotes radioresistance,
invasion, and metastasis in lung cancer via p53 signaling pathway.
Aging (Albany NY). 16:7060–7072. 2024.PubMed/NCBI
|
|
57
|
Diaz LA and Bardelli A: Liquid biopsies:
Genotyping circulating tumor DNA. J Clin Oncol. 32:579–586. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Perillo A, Olufemi MVA, De Robbio J,
Mancuso RM, Roscigno A, Tirozzi M and Scognamiglio IR: Liquid
biopsy in NSCLC: A new challenge in radiation therapy. Explor
Target Antitumor Ther. 2:156–173. 2021.PubMed/NCBI
|
|
59
|
Osumi H, Shinozaki E, Yamaguchi K and
Zembutsu H: Clinical utility of circulating tumor DNA for
colorectal cancer. Cancer Sci. 110:1148–1155. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yun HS, Baek JH, Yim JH, Um HD, Park JK,
Song JY, Park IC, Kim JS, Lee SJ, Lee CW and Hwang SG: Radiotherapy
diagnostic biomarkers in radioresistant human H460 lung cancer
stem-like cells. Cancer Biol Ther. 17:208–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Nguyen GH, Murph MM and Chang JY: Cancer
stem cell radioresistance and enrichment: Where frontline radiation
therapy may fail in lung and esophageal cancers. Cancers (Basel).
3:1232–1252. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Afsar CU and Uysal P: HIF-1α Levels in
patients receiving chemoradiotherapy for locally advanced non-small
cell lung carcinoma. Rev Assoc Med Bras. 65:1295–1299. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang Y, Liu X, Zeng L, Zhao X, Chen Q,
Pan Y, Bai Y, Shao C and Zhang J: Exosomal protein
angiopoietin-like 4 mediated radioresistance of lung cancer by
inhibiting ferroptosis under hypoxic microenvironment. Br J Cancer.
127:1760–1772. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ostheimer C, Gunther S, Bache M,
Vordermark D and Multhoff G: Dynamics of heat shock protein 70
serum levels as a predictor of clinical response in Non-Small-Cell
lung cancer and correlation with the Hypoxia-Related marker
osteopontin. Front Immunol. 8:13052017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ostheimer C, Bache M, Güttler A, Kotzsch M
and Vordermark D: A pilot study on potential plasma hypoxia markers
in the radiotherapy of non-small cell lung cancer. Strahlenther
Onkol. 190:276–282. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Dehing-Oberije C, Aerts H, Yu S, De
Ruysscher D, Menheere P, Hilvo M, van der Weide H, Rao B and Lambin
P: Development and validation of a prognostic model using blood
biomarker information for prediction of survival of non-small-cell
lung cancer patients treated with combined chemotherapy and
radiation or radiotherapy alone (NCT00181519, NCT00573040, and
NCT00572325). Int J Radiat Oncol Biol Phys. 81:360–368. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Sui X, Jiang L, Teng H, Mi L, Li B, Shi A,
Yu R, Li D, Dong X, Yang D, et al: Prediction of clinical outcome
in locally advanced Non-Small cell lung cancer patients treated
with chemoradiotherapy by plasma markers. Front Oncol.
10:6259112021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Li K, Wang S, Li N, Zhao W, He N, Wang J,
Ji K, Zhang M, Song H, Liu Q and Du L: Prognostic biomarkers after
radiotherapy for nonsmall cell lung cancer based on bioinformatics
analysis. Biomed Res Int. 2022:64052282022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Yao G, Tang J, Yang X, Zhao Y, Zhou R,
Meng R, Zhang S, Dong X, Zhang T, Yang K, et al: Cyclin K interacts
with β-catenin to induce Cyclin D1 expression and facilitates
tumorigenesis and radioresistance in lung cancer. Theranostics.
10:11144–11158. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Cheng C, Pei X, Li SW, Yang J, Li C, Tang
J, Hu K, Huang G, Min WP and Sang Y: CRISPR/Cas9 library screening
uncovered methylated PKP2 as a critical driver of lung cancer
radioresistance by stabilizing β-catenin. Oncogene. 40:2842–2857.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Baek JH, Yun HS, Kwon GT, Lee J, Kim JY,
Jo Y, Cho JM, Lee CW, Song JY, Ahn J, et al: PLOD3 suppression
exerts an anti-tumor effect on human lung cancer cells by
modulating the PKC-delta signaling pathway. Cell Death Dis.
10:1562019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Li J, Zong Y, Tuo Z and Liu J and Liu J:
The role of RASA2 in predicting radioresistance in lung cancer
through regulation of p53. Transl Lung Cancer Res. 13:587–602.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen Y, Zhou Y, Feng X, Wu Z, Yang Y, Rao
X, Zhou R, Meng R, Dong X, Xu S, et al: Targeting FBXO22 enhances
radiosensitivity in non-small cell lung cancer by inhibiting the
FOXM1/Rad51 axis. Cell Death Dis. 15:1042024. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Ji NN, Li SN, Shao L, Li Q, Xu JN and Zeng
YC: MDMX enhances radiosensitivity in lung adenocarcinoma and
squamous cell carcinoma by inhibiting P53-mediated autophagy. Cell
Oncol. 48:1067–1088. 2025. View Article : Google Scholar
|
|
75
|
Reno KE, Costa-Terryll A, Park SH, Hughes
RT, Farris MK, Xing F and Willey JS: Cartilage oligomeric matrix
protein promotes radiation resistance in non-small cell lung cancer
in vitro. Int J Mol Sci. 26:24652025. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Zhang R, Yan W, Yuan J, Ma Y, Ren Z, Chen
X, Lv J, Wu M, Yu J and Chen D: Cancer-associated
fibroblast-derived fibulin-5 promotes radioresistance in
non-small-cell lung cancer. Cell Rep. 44:1160182025. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Wang Y, Meng L, Meng S, Huang L, Luo S, Wu
X and Gong X: Flotillin-1 enhances radioresistance through reducing
radiation-induced DNA damage and promoting immune escape via STING
signaling pathway in non-small cell lung cancer. Cancer Biol Ther.
24:22033322023. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Alessi JV, Ricciuti B, Wang X, Pecci F, Di
Federico A, Lamberti G, Elkrief A, Rodig SJ, Lebow ES, Eicholz JE,
et al: Impact of TMB/PD-L1 expression and pneumonitis on
chemoradiation and durvalumab response in stage III NSCLC. Nat
Commun. 14:42382023. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lei Z, He J, Yang H, Zhang L, Lai T, Zhou
L, Tang Z, Sui J and Wu Y: Global profiling of transcriptome,
proteome and 2-hydroxyisobutyrylome in radioresistant lung
adenocarcinoma cell. BMC Genomics. 25:9232024. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Delikgoz Soykut E, Kemal Y, Karacin C,
Karaoglanoglu O, Kurt M and Aytac Arslan S: Prognostic impact of
immune inflammation biomarkers in predicting survival and
radiosensitivity in patients with non-small-cell lung cancer
treated with chemoradiotherapy. J Med Imaging Radiat Oncol.
66:146–157. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Kim EH, Park AK, Dong SM, Ahn JH and Park
WY: Global analysis of CpG methylation reveals epigenetic control
of the radiosensitivity in lung cancer cell lines. Oncogene.
29:4725–4731. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Pernía O, Belda-Iniesta C, Pulido V,
Cortes-Sempere M, Rodriguez C, Vera O, Soto J, Jiménez J, Taus A,
Rojo F, et al: Methylation status of IGFBP-3 as a useful clinical
tool for deciding on a concomitant radiotherapy. Epigenetics.
9:1446–1453. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Koturbash I and Griffin RJ: Harnessing
epigenetics and metabolism to modulate tissue response to
radiotherapy. Int J Radiat Biol. 95:379–381. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Hammond SM: An overview of microRNAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Angerilli V, Galuppini F, Businello G, Dal
Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V,
Lonardi S, et al: MicroRNAs as predictive biomarkers of resistance
to targeted therapies in gastrointestinal tumors. Biomedicines.
9:3182021. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Salim H, Akbar NS, Zong D, Vaculova AH,
Lewensohn R, Moshfegh A, Viktorsson K and Zhivotovsky B: miRNA-214
modulates radiotherapy response of non-small cell lung cancer cells
through regulation of p38MAPK, apoptosis and senescence. Br J
Cancer. 107:1361–1373. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Yuan Y, Liao H, Pu Q, Ke X, Hu X, Ma Y,
Luo X, Jiang Q, Gong Y, Wu M, et al: miR-410 induces both
epithelial-mesenchymal transition and radioresistance through
activation of the PI3K/mTOR pathway in non-small cell lung cancer.
Signal Transduct Target Ther. 5:852020. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Lv J, An J, Zhang YD, Li ZX, Zhao GL, Gao
J, Hu WW, Chen HM, Li AM and Jiang QS: A three serum miRNA panel as
diagnostic biomarkers of radiotherapy-related metastasis in
non-small cell lung cancer. Oncol Lett. 20:2362020. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Chen X, Xu Y, Liao X, Liao R, Zhang L, Niu
K, Li T, Li D, Chen Z, Duan Y and Sun J: Plasma miRNAs in
predicting radiosensitivity in non-small cell lung cancer. Tumor
Biol. 37:11927–11936. 2016. View Article : Google Scholar
|
|
90
|
Chen X, Wu L, Li D, Xu Y, Zhang L, Niu K,
Kong R, Gu J, Xu Z, Chen Z and Sun J: Radiosensitizing effects of
miR-18a-5p on lung cancer stem-like cells via downregulating both
ATM and HIF-1α. Cancer Med. 7:3834–3847. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Zhang Y and Hu X: miR-148a promotes cell
sensitivity through downregulating SOS2 in radiation-resistant
non-small cell lung cancer cells. Oncol Lett. 23:1352022.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Han F, Huang D, Huang X, Wang W, Yang S
and Chen S: Exosomal microRNA-26b-5p down-regulates ATF2 to enhance
radiosensitivity of lung adenocarcinoma cells. J Cell Mol Med.
24:7730–7742. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang Y and Xu H: Serum exosomal miR-378
upregulation is associated with poor prognosis in non-small-cell
lung cancer patients. J Clin Lab Anal. 34:e232372020. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Santosh B, Varshney A and Yadava PK:
Non-coding RNAs: Biological functions and applications. Cell
Biochem Funct. 33:14–22. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Fu W, Zhao J, Hu W, Dai L, Jiang Z, Zhong
S, Deng B, Huang Y, Wu W and Yin J: LINC01224/ZNF91 promote stem
cell-like properties and drive radioresistance in Non-small cell
lung cancer. Cancer Manag Res. 13:5671–5681. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Song J, Zhang S, Sun Y, Gu J, Ye Z, Sun X
and Tang Q: A Radioresponse-related lncRNA biomarker signature for
risk classification and prognosis prediction in non-small-cell lung
cancer. J Oncol. 2021:43388382021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wang Z, Liu L, Du Y, Mi Y and Wang L: The
HNF1A-AS1/miR-92a-3p axis affects the radiosensitivity of non-small
cell lung cancer by competitively regulating the JNK pathway. Cell
Biol Toxicol. 37:715–729. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Brownmiller T, Juric JA, Ivey AD, Harvey
BM, Westemeier ES, Winters MT, Stevens AM, Stanley AN, Hayes KE,
Sprowls SA, et al: Y chromosome LncRNA are involved in radiation
response of male Non-Small cell lung cancer cells. Cancer Res.
80:4046–4057. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Gu A, Li J, Li MY and Liu Y:
Patient-derived xenograft model in cancer: Establishment and
applications. MedComm. 6:e700592025. View Article : Google Scholar : PubMed/NCBI
|
